The renal cell carcinoma (RCC) is one of the most common types of kidney neoplasia in Western countries; it is relatively resistant to conventional chemotherapy and radiotherapy. Metabolic disorders have a profound effect on the degree of malignancy and treatment resistance of the tumor.
However, the molecular characteristics related to impaired metabolism leading to the initiation of RCC are still not very clear. In this study, two-dimensional electrophoresis (2-DE) and mass spectra (MS) technologies were utilized to identify the proteins involved in energy metabolism of RCC. A total of 73 proteins that were differentially expressed in conventional RCC, in comparison with the corresponding normal kidney tissues, were identified. Bioinformatics analysis has shown that these proteins are involved in glycolysis, urea cycle, and the metabolic pathways of pyruvate, propanoate, and arginine/proline. In addition, some were also involved in the signaling network of p53 and FAS. These results provide some clues for new therapeutic targets and treatment strategies of RCC.
OncoTargets and therapy. 2016 Mar 09*** epublish ***
Zejun Lu, Yuqin Yao, Qi Song, Jinliang Yang, Xiangfei Zhao, Ping Yang, Jingbo Kang
Department of Radiation Oncology, Naval General Hospital of People's Liberation Army, Beijing, Chengdu, People's Republic of China., Research Center for Public Health and Preventive Medicine, West China School of Public Health/No 4 West China Teaching Hospital, Sichuan University, Chengdu, Chengdu, People's Republic of China., Department of Gynaecology and Obstetrics, The General Hospital of Chinese People's Armed Police Force, Beijing, Chengdu, People's Republic of China., State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Department of Radiation Oncology, Naval General Hospital of People's Liberation Army, Beijing, Chengdu, People's Republic of China., Department of Radiation Oncology, Naval General Hospital of People's Liberation Army, Beijing, Chengdu, People's Republic of China., Department of Radiation Oncology, Naval General Hospital of People's Liberation Army, Beijing, Chengdu, People's Republic of China.